TimeScale Financial’s Acadia Pharmaceuticals ACAD Stock Holding History

TimeScale Financial’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-100	Closed	-$2K	–	510
2022 Q1	$2K	Hold	100	–	–	﹤0.01%	430
2021 Q4	$2K	Hold	100	–	–	﹤0.01%	427
2021 Q3	$2K	Hold	100	–	–	﹤0.01%	422
2021 Q2	$2K	Hold	100	–	–	﹤0.01%	423
2021 Q1	$3K	Hold	100	–	–	﹤0.01%	415
2020 Q4	$5K	Hold	100	–	–	﹤0.01%	327
2020 Q3	$4K	Buy	+100	New	+$4.32K	﹤0.01%	365

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TimeScale Financial's ACAD Position: Q2 2022 in Review

TimeScale Financial sold out of Acadia Pharmaceuticals (ACAD) in Q2 2022, closing a stake of 100 shares — an estimated $2K sold.

TimeScale Financial first reported a position in ACAD in Q3 2020 and held it in 7 quarters. The position peaked at $5K in Q4 2020. 246 funds tracked by Wall St. Rank hold ACAD as of Q2 2022.

TimeScale Financial reported no remaining Acadia Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
TimeScale Financial sold 100 Acadia Pharmaceuticals shares in Q2 2022, an estimated $2K.
TimeScale Financial first reported a position in Acadia Pharmaceuticals in Q3 2020 and held it in 7 quarters.
TimeScale Financial's Acadia Pharmaceuticals position peaked at $5K in Q4 2020.
246 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2022.

Based on TimeScale Financial's 13F filing for Q2 2022, filed 25 Jul 2022.